Clinical Trial Update: ECC5004 RBA FE Study in Healthy Participants [Phase 1]

View source ↗

Summary

ECC5004 RBA FE Phase 1 study in healthy participants has completed, evaluating safety and pharmacology in humans for potential use in Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ECC5004 RBA FE

Snippet

Sponsor: Eccogene | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED